Pulse Biosciences Receives FDA Breakthrough Device Designation For Cardiac Surgery System Using Nanosecond Pulsed Field Ablation Technology For Treating Atrial Fibrillation
Portfolio Pulse from Benzinga Newsdesk
Pulse Biosciences has received FDA Breakthrough Device Designation for its cardiac surgery system that uses nanosecond pulsed field ablation technology to treat atrial fibrillation.
July 08, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pulse Biosciences has received FDA Breakthrough Device Designation for its cardiac surgery system using nanosecond pulsed field ablation technology to treat atrial fibrillation. This designation could accelerate the development and approval process, potentially boosting the company's stock price.
The FDA Breakthrough Device Designation is a significant milestone that can expedite the development and approval process of Pulse Biosciences' new technology. This could lead to faster market entry and potential revenue growth, positively impacting the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100